Table 1.
Summary of rAAV transduction
| Vector | Cat # | Eye #, OS/OD |
Concentration | In vivo assessment | Histological assessment | |||
|---|---|---|---|---|---|---|---|---|
| Onset of fluorescence (days) |
Onset by vector (days; range, mean) |
% cones transduced |
% rods transduced |
Rods versus cones; P, test | ||||
| rAAV2/2 | 1 | 1, OS | 1011 vgml−1 | 3 | 3–4, 3.3 (SD = 0.87) | 78% (SD = 19) | 6% (SD = 3) | P = 0.0033, two-tailed t-test |
| 2 | 2, OS | 1011 vgml−1 | 4 | |||||
| 3 | 3, OS | 1011 vgml−1 | 4, excludeda | |||||
| 4 | 4, OS | 1011 vgml−1 | Excludedb | |||||
| rAAV2/5 | 5 | 1, OD | 1011 vgml−1 | 7 | 4–7, 5.1 (SD = 1.86) | 74% (SD = 20) | 15% (SD = 13) | P = <0.000, two-tailed t-test |
| 6 | 2, OD | 1011 vgml−1 | 7 | |||||
| 7 | 3, OD | 1011 vgml−1 | 6 | |||||
| 8 | 4, OD | 1011 vgml−1 | UTD+ | |||||
| 9 | 5, OD | 1011 vgml−1 | 4 | |||||
| 10 | 6, OD | 1011 vgml−1 | 4 | |||||
| rAAV2/8 | 5 | 1, OS | 1011 vgml−1 | 3 | 1–3, 2.4 (SD = 0.77) | 85% (SD = 13) | 18% (SD = 25) | P = <0.001, Mann–Whitney rank sum test |
| 6 | 2, OS | 1011 vgml−1 | 2 | |||||
| 7 | 3, OS | 1011 vgml−1 | 1 | |||||
| 8 | 4, OS | 1011 vgml−1 | 3 | |||||
| 9 | 5, OS | 1011 vgml−1 | 3 | |||||
| 10 | 6, OS | 1011 vgml−1 | 2 | |||||
| rAAV2/9 | 1 | 1, OD | 1011 vgml−1 | 3, excludeda | 2–3, 2.6 (SD = 0.55) | 51% (SD = 13) | 4% (SD = 0.6) | P =0.0028, two-tailed t-test |
| 2 | 2, OD | 1011 vgml−1 | 2 | |||||
| 3 | 3, OD | 1011 vgml−1 | Excludedb | |||||
| 4 | 4, OD | 1011 vgml−1 | Excludedb | |||||
Key:
+
UTD: unable to determine; Vitreal hemorrhage precluded fundus examination.
a
Excluded from histological analysis only, because of poor section quality. Please refer to methods for histological assessment procedure.
b
Excluded because of inflammation that developed immediately postoperatively.